https://www.selleckchem.com/pr....oducts/SB-203580.htm
patients. Further studies in larger study populations are required to verify these results.BACKGROUND Use of direct-acting oral anticoagulants for patients with nonvalvular atrial fibrillation (NVAF) in skilled nursing facilities (SNFs) is increasing. Rivaroxaban is commonly used in this setting as an alternative to warfarin, based on comparable or increased efficacy in preventing stroke and a similar or lower risk of major bleeding. OBJECTIVE The aim of this study was to compare healthcare resource utilization (HCRU) and costs betwee